Merimepodib Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 387

Clinical Trials

Merimepodib has been evaluated in multiple Phase 2 clinical trials investigating its efficacy against viral infections, specifically chronic Hepatitis C and COVID-19. A Phase 2 trial sponsored by Vertex Pharmaceuticals Incorporated evaluating combination therapy for Hepatitis C was completed. Conversely, a Phase 2 trial sponsored by ViralClear Pharmaceuticals, Inc. investigating oral combination therapy for COVID-19 was terminated.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04410354	TERMINATED	COVID-19	ViralClear Pharmaceuticals, Inc.	2020-06-16	PHASE2
NCT00088504	COMPLETED	Hepatitis C; Hepatitis	Vertex Pharmaceuticals Incorporated	2004-07	PHASE2

(data from https://clinicaltrials.gov, updated on 2020-12-08)

Check the Merimepodib product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Merimepodib reversibly binds to and inhibits inosine monophosphate dehydrogenase, thereby depleting intracellular guanine nucleotide pools necessary for nucleic acid synthesis. This metabolic block suppresses viral genome replication and immune cell expansion, highlighting its clinical evaluation for therapeutic intervention in viral conditions such as Hepatitis C and COVID-19.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).